REVIEW - CellCept: what is its place in the treatment of autoimmune rheumatic diseases?

[Guest guest]

Autoimmun Rev. 2007 Jan;6(3):190-5. Epub 2006 Dec 1.

Mycophenolate mofetil: what is its place in the treatment of

autoimmune rheumatic diseases?

Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A.

Division of Rheumatology, Department of Clinical and Experimental

Medicine, University of Padova, Via Giustiniani, 2, 35128 Padova,

Italy.

Mycophenolate mofetil (MMF) is a new immunosuppressant recently

introduced in the treatment of autoimmune conditions. The greatest

experience with the use of MMF has been achieved in the treatment of

proliferative lupus glomerulonephritis. However, MMF has also been

used to control SLE extra-renal manifestations as well as other

autoimmune rheumatic diseases such as idiopathic inflammatory

arthropathies, inflammatory myopathies, systemic sclerosis, and

systemic vasculitis. MMF seems to be well tolerated and effective and

could be considered a useful alternative to standard

immunosuppressants for the treatment of autoimmune rheumatic

disorders. However, further studies are needed in order to determine

its real place in the treatment of these conditions. In this paper,

the use of MMF in different autoimmune rheumatic diseases is reviewed

and discussed.

PMID: 17289556

http://www.ncbi.nlm.nih.gov/pubmed/17289556

--

Not an MD